Copertina

Analysis of Antroduodenal Motility in Patients With Hypermobility Spectrum Disorders/Hypermobile Ehlers–Danlos Syndrome

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kim W. E. Sweerts, Zlatan Mujagic, Daniel Keszthelyi, José M. Conchillo
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
di: Kim W. E. Sweerts, et al.
Pubblicazione: (2025)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
di: Arta Aliu, et al.
Pubblicazione: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
di: Arta Aliu, et al.
Pubblicazione: (2024)

Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
di: Fleur Veldman, et al.
Pubblicazione: (2026)

Letter: Gastroparesis in Lung Transplantation: Time to Reframe and Standardise Post‐Transplant Foregut Motility Evaluation
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas‐Sensing Wireless Motility Capsules
di: Phoebe A. Thwaites, et al.
Pubblicazione: (2025)

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors
di: Philip Kitchen, et al.
Pubblicazione: (2026)

Letter: Gastroparesis in Lung Transplantation: Time to Reframe and Standardize Post‐Transplant Foregut Motility Evaluation: Authors' Reply
di: Mohamed H. Eldesouki, et al.
Pubblicazione: (2026)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
di: Quinn Goddard, et al.
Pubblicazione: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System
di: Neil S. Zheng, et al.
Pubblicazione: (2025)

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
di: Vivek C. Goodoory, et al.
Pubblicazione: (2026)

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies
di: Jasmohan S. Bajaj, et al.
Pubblicazione: (2025)

Letter on ‘Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas‐Sensing Wireless Motility Capsules’: Authors' Reply
di: Phoebe A. Thwaites, et al.
Pubblicazione: (2025)

Women's Health Disorders in a Coeliac Disease Population After Diagnosis—A Nationwide Cohort Analysis
di: Rama Nanah, et al.
Pubblicazione: (2025)

Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients
di: Mohamed H. Eldesouki, et al.
Pubblicazione: (2026)

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis
di: Luke D. Tyson, et al.
Pubblicazione: (2026)

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
di: Lesley A. Houghton, et al.
Pubblicazione: (2025)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
di: Nauzer Forbes, et al.
Pubblicazione: (2024)

Stability of Classification Systems for Irritable Bowel Syndrome
di: Mais Khasawneh, et al.
Pubblicazione: (2025)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
di: E. Coss‐Adame, et al.
Pubblicazione: (2026)

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
di: T. E. Conley, et al.
Pubblicazione: (2026)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
di: Matheus Souza, et al.
Pubblicazione: (2025)

Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome—A Prospective Longitudinal Multicentre Study
di: Elsa L. S. A. van Liere, et al.
Pubblicazione: (2024)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
di: Kunhee Kim, et al.
Pubblicazione: (2024)

Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome
di: Mohsin F. Butt, et al.
Pubblicazione: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation
di: Xidi Yang, et al.
Pubblicazione: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Editorial: Disorders of gut‐brain interaction—Don't forget the older person
di: Christopher J. Black
Pubblicazione: (2024)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
di: Brent A. Neuschwander‐Tetri, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
di: Glenn Jun Kit Ho, et al.
Pubblicazione: (2025)

Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome
di: Andrea Shin, et al.
Pubblicazione: (2025)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’
di: James Turvill
Pubblicazione: (2025)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
di: Vivek C. Goodoory, et al.
Pubblicazione: (2024)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
di: Christopher L. Bowlus, et al.
Pubblicazione: (2025)